Chediak–Higashi syndrome
Chediak–Higashi syndrome (CHS) is a rare autosomal recessive genetic disorder that primarily affects the immune system. It is characterized by a reduced ability to fight off infections, partial albinism, and a range of other symptoms. The syndrome is named after the two physicians who first described it, Cuban doctor Alexis Chediak and Japanese doctor Toru Higashi.
Etiology[edit | edit source]
CHS is caused by mutations in the LYST gene, which is involved in the regulation of lysosome size and function. The mutations lead to the formation of abnormally large lysosomes in various types of cells, including white blood cells that play a crucial role in the immune response.
Symptoms and Signs[edit | edit source]
The most common symptoms of CHS include partial albinism, leading to light skin and hair color, and problems with the immune system, which can result in frequent infections. Other symptoms can include neurological disorders, bleeding disorders, and an enlarged liver and spleen.
Diagnosis[edit | edit source]
Diagnosis of CHS is typically based on the presence of characteristic clinical symptoms, the identification of abnormally large lysosomes in white blood cells, and genetic testing to identify mutations in the LYST gene.
Treatment[edit | edit source]
There is currently no cure for CHS. Treatment is primarily supportive and aimed at managing the symptoms. This can include antibiotics to treat infections, blood transfusions to manage bleeding disorders, and in severe cases, bone marrow transplantation.
Prognosis[edit | edit source]
The prognosis for individuals with CHS varies. Some individuals have a relatively mild form of the disease and can live into adulthood, while others have a more severe form that can lead to early death, often due to infections or complications of the neurological disorder.
See Also[edit | edit source]
NIH genetic and rare disease info[edit source]
Chediak–Higashi syndrome is a rare disease.
| Chediak–Higashi syndrome Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
